Universal Biosensors, Inc (UBI) Fair Value & Analysis
Healthcare · AU · Market cap A$4.2M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.2600 to A$0.0162 (−93.8%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range A$0.0140 – A$0.0350 · fair‑value band A$0.0148 – A$0.0176 · the A$0.0140 price screens below the A$0.0162 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Universal Biosensors, Inc (UBI) currently trades at A$0.0140, while our model-based Fair Value estimate is A$0.0162 — implying the stock looks roughly 16.0% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$6.0M. Revenue declined 25.6% year over year. The balance sheet holds a net cash position of A$4.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Universal Biosensors, Inc reported revenue of A$6.3M in FY2024 versus A$3.2M in FY2020, a compound +18.3%/yr. Reported net income was −A$14.2M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Universal Biosensors, Inc (UBI) undervalued?
What is the fair value of UBI?
What is the quality score of UBI?
What is the revenue of Universal Biosensors, Inc (UBI)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.